RICHMOND, Va., Oct 26, 2004 (BUSINESS WIRE) -- Insmed Incorporated (NASDAQ: INSM) today announced that Geoffrey Allan, Ph.D., President and Chief Executive Officer of Insmed, will present this Thursday, October 28, 2004 at 9:25am ET during the Rodman and Renshaw Healthcare Conference. The conference is being held October 26-28, 2004 at the Waldorf-Astoria in New York.
A live audio webcast of the Company's presentation can be accessed by going to Insmed's corporate web site at www.insmed.com. A replay of the presentation will be available for 30 days.
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for the treatment of metabolic diseases with unmet medical needs. Insmed's most advanced product, SomatoKine(R), is currently in a pivotal Phase III clinical trial for the treatment of Growth Hormone Insensitivity Syndrome (GHIS). On July 20, Insmed provided the results from a six-month data analysis of the ongoing pivotal Phase III GHIS clinical trial showing a statistically significant increase (p
Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release.
